[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-563549-105":53,"doc-detail-563549-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","prapo-semaglutide-injection-antihyperglycemic-agent-glp-1-receptor-agonist-product-monograph-including-patient-medication-information","PrAPO-SEMAGLUTIDE INJECTION - Antihyperglycemic Agent (GLP-1 Receptor Agonist) - Product Monograph Including Patient Medication Information","","PrAPO-SEMAGLUTIDE INJECTION is an antihyperglycemic agent formulated as a solution for subcutaneous injection in pre-filled pens. It is produced by solid-phase synthetic chemistry and is presented in 2 mg and 4 mg strengths per pen, with specified concentrations and pre-filled dose options (0.25/0.5 mg and 1 mg). The monograph includes sections for indications by population, contraindications, serious warnings and precautions, dosing and administration, overdose, composition and packaging, warnings and precautions, adverse reactions, drug interactions, clinical pharmacology, and storage, stability, and disposal.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/prapo-semaglutide-injection-antihyperglycemic-agent-glp-1-receptor-agonist-product-monograph-including-patient-medication-information/563549/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/prapo-semaglutide-injection-antihyperglycemic-agent-glp-1-receptor-agonist-product-monograph-including-patient-medication-information/563549.png","ImageObject",442,249,{"name":88,"@type":89},"pop out","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-26","2026-10-12",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",8,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What is PrAPO-SEMAGLUTIDE INJECTION and how is it administered?","Question",{"text":109,"@type":110},"It is an antihyperglycemic agent formulated as a solution for subcutaneous injection in pre-filled pens. The monograph specifies dosing by pen-delivered dose options.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What populations are covered for indications and special warnings?",{"text":114,"@type":110},"Indications and warnings include sections for pediatrics and geriatrics, and special populations include pregnancy, breastfeeding, pediatrics, geriatrics, renal insufficiency, and hepatic insufficiency.",{"name":116,"@type":107,"acceptedAnswer":117},"What topics are included regarding safety, interactions, and pharmacology?",{"text":118,"@type":110},"The monograph covers contraindications, serious warnings and precautions, adverse reactions (including clinical trial and post-market), drug interactions (overview and interaction types), and clinical pharmacology such as mechanism of action, pharmacodynamics, pharmacokinetics, and immunogenicity.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},563549,1792086596,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":141,"read_time":142},962090760408,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Product Monograph Including Patient Medication Information  \nPrAPO-SEMAGLUTIDE INJECTION  \nSolution for Subcutaneous Injection in a pre-filled pen Produced by solid-phase synthetic chemistry  \n2 mg / pen (0 .68 mg / mL)  \n4 mg / pen (1 .34 mg / mL)  \nPre-filled pen delivering doses of 0.25 mg or 0.5 mg  \nand  \nPre-filled pen delivering doses of 1 mg  \nAntihyperglycemic Agent  \nGlucagon-like Peptide-1 (GLP-1) Receptor Agonist  \nAPOTEX INC.  \n150 Signet Drive Toronto, Ontario M9L 1T9  \nDate of Authorization: 2026-05-01  \nControl Number: 290796  \nRecent Major Label Changes  \nNone at time of the most recent authorization  \nTable of Contents  \nCertain sections or subsections that are not applicable at the time of the preparation of the most  \nrecent authorized product monograph are not listed.  \nRecent Major Label Changes .................................................................................................. 2  \nTable of Contents..................................................................................................................... 2  \nPart 1: Healthcare Professional Information .......................................................................... 4  \n1 Indications .................................................................................................................... 4  \n1.1 Pediatrics .................................................................................................................... 4  \n1.2 Geriatrics .................................................................................................................... 4  \n2 Contraindications ......................................................................................................... 4  \n3 Serious Warnings and Precautions Box ..................................................................... 5  \n4 Dosage and Administration ......................................................................................... 5  \n4.1 Dosing Considerations ............................................................................................... 5  \n4.2 Recommended Dose and Dosage Adjustment........................................................... 5  \n4.4 Administration ............................................................................................................. 6  \n4.5 Missed Dose ............................................................................................................... 6  \n5 Overdose ....................................................................................................................... 6  \n6 Dosage Forms, Strengths, Composition and Packaging........................................... 7  \n7 Warnings and Precautions .......................................................................................... 8  \n7.1 Special Populations .................................................................................................. 11  \n7.1.1 Pregnancy.................................................................................................12  \n7.1.2 Breastfeeding ...........................................................................................12  \n7.1.3 Pediatrics .................................................................................................12  \n7.1.4 Geriatrics .................................................................................................12  \n7.1.5 Renal Insufficiency ...................................................................................12  \n7.1.6 Hepatic Insufficiency ................................................................................12  \n8 Adverse Reactions ......................................................................................................13  \n8.1 Adverse Reaction Overview ..................................................................................... 13  \n8.2 Clinical Trial Adverse Reactions .....................................................................","cbCaitVtXCE957zl","https://ap.wps.com/l/cbCaitVtXCE957zl","pdf",1305076,63,"English","# Part 1: Healthcare Professional Information\n## 1 Indications\n### 1.1 Pediatrics\n### 1.2 Geriatrics\n## 2 Contraindications\n## 3 Serious Warnings and Precautions Box\n## 4 Dosage and Administration\n### 4.1 Dosing Considerations\n### 4.2 Recommended Dose and Dosage Adjustment\n### 4.4 Administration\n### 4.5 Missed Dose\n## 5 Overdose\n## 6 Dosage Forms, Strengths, Composition and Packaging\n## 7 Warnings and Precautions\n### 7.1 Special Populations\n### 7.1.1 Pregnancy\n### 7.1.2 Breastfeeding\n### 7.1.3 Pediatrics\n### 7.1.4 Geriatrics\n### 7.1.5 Renal Insufficiency\n### 7.1.6 Hepatic Insufficiency\n## 8 Adverse Reactions\n### 8.1 Adverse Reaction Overview\n### 8.2 Clinical Trial Adverse Reactions\n### 8.3 Less Common Clinical Trial Adverse Reactions\n### 8.5 Post-Market Adverse Reactions\n## 9 Drug Interactions\n### 9.2 Drug Interactions Overview\n### 9.3 Drug-Behaviour Interactions\n### 9.4 Drug-Drug Interactions\n### 9.5 Drug-Food Interactions\n### 9.6 Drug-Herb Interactions\n### 9.7 Drug-Laboratory Test Interactions\n## 10 Clinical Pharmacology\n### 10.1 Mechanism of Action\n### 10.2 Pharmacodynamics\n### 10.3 Pharmacokinetics\n### 10.4 Immunogenicity\n## 11 Storage, Stability and Disposal\n## 12 Special Handling Instructions","[{\"question\":\"What is PrAPO-SEMAGLUTIDE INJECTION and how is it administered?\",\"answer\":\"It is an antihyperglycemic agent formulated as a solution for subcutaneous injection in pre-filled pens. The monograph specifies dosing by pen-delivered dose options.\"},{\"question\":\"What populations are covered for indications and special warnings?\",\"answer\":\"Indications and warnings include sections for pediatrics and geriatrics, and special populations include pregnancy, breastfeeding, pediatrics, geriatrics, renal insufficiency, and hepatic insufficiency.\"},{\"question\":\"What topics are included regarding safety, interactions, and pharmacology?\",\"answer\":\"The monograph covers contraindications, serious warnings and precautions, adverse reactions (including clinical trial and post-market), drug interactions (overview and interaction types), and clinical pharmacology such as mechanism of action, pharmacodynamics, pharmacokinetics, and immunogenicity.\"}]","PrAPO-SEMAGLUTIDE INJECTION - Antihyperglycemic Agent (GLP-1 Receptor Agonist) - Product Monograph Including Patient Medication Information | PDF",1791836432,22]